Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2016

Open Access 01-12-2016 | Case report

Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report

Authors: Yiming Tian, Rui Wang, Lianyuan Liu, Chunming Ma, Qiang Lu, Fuzai Yin

Published in: BMC Musculoskeletal Disorders | Issue 1/2016

Login to get access

Abstract

Background

Zoledronic acid-induced uveitis (ZAIU) is rare but severe, and has been recently considered part of an acute phase reaction. Only 15 cases have been reported since 2005. Here we describe a case with macular edema, which is the first reported case observed after long-term alendronate tolerance.

Case presentation

A 63-year-old Asian woman received her first intravenous zoledronic acid treatment for the management of postmenopausal osteoporosis as a more convenient substitute for oral alendronate. Twenty-four hours later, bilateral eye irritations, periorbital swelling, blurred vision, and diplopia presented. The complete blood count and transaminase levels were normal, but the erythrocytic sedimentation, C-reactive protein, and serum C4 levels were elevated. On detailed ophthalmological examination, a diagnosis of bilateral acute uveitis and macular edema in the right eye was made. The ocular symptoms were not improved until administration of topical and oral steroids. Complete resolution was achieved. There was no rechallenge of bisphosphonates, and no recurrence at 6 months follow-up. Based on an extensive review, abnormal fundus is rarely reported, especially in cases of macular edema. Rechallenge with zoledronic acid in five cases induced no additional uveitis, and changing the medication to pamidronate in another patient was also tolerated. Interestingly, our patient suffered from uveitis soon after intravenous zoledronate exposure after a two-year tolerance to oral alendronate.

Conclusions

This is the first report of zoledronic acid induced uveitis with macular edema after long-term alendronate tolerance. Prior oral alendronate may not entirely prevent ZAIU. Steroids are usually necessary in the treatment of ZAIU. Bisphosphonate rechallenge is not fully contraindicated, and prior steroid administration may be a more reasonable treatment choice according to the available evidence.
Literature
1.
go back to reference Bobba RS, Beattie K, Parkinson B, Kumbhare D, Adachi JD. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf. 2006;29(12):1133–52.CrossRefPubMed Bobba RS, Beattie K, Parkinson B, Kumbhare D, Adachi JD. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf. 2006;29(12):1133–52.CrossRefPubMed
2.
go back to reference French DD, Margo CE. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina. 2008;28(6):889–93.CrossRefPubMed French DD, Margo CE. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina. 2008;28(6):889–93.CrossRefPubMed
3.
go back to reference Patel DV, Bolland M, Nisa Z, Al-Abuwsi F, Singh M, Horne A, et al. Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial. Osteoporos Int. 2015;26(2):499–5.CrossRefPubMed Patel DV, Bolland M, Nisa Z, Al-Abuwsi F, Singh M, Horne A, et al. Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial. Osteoporos Int. 2015;26(2):499–5.CrossRefPubMed
4.
go back to reference Patel DV, Horne A, House M, Reid IR, McGhee CN. The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology. 2013;120(4):773–6.CrossRefPubMed Patel DV, Horne A, House M, Reid IR, McGhee CN. The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology. 2013;120(4):773–6.CrossRefPubMed
5.
go back to reference Freitas-Neto CA, de Oliveira Fagundes WB, Ribeiro Jr M, Pacheco KD, Freitas LG, Avila MP. Unilateral Uveitis with Vitreous Haze Following Zoledronic Acid Therapy for Osteoporosis. Semin Ophthalmol. 2013. doi:10.1007/s801090000086.PubMed Freitas-Neto CA, de Oliveira Fagundes WB, Ribeiro Jr M, Pacheco KD, Freitas LG, Avila MP. Unilateral Uveitis with Vitreous Haze Following Zoledronic Acid Therapy for Osteoporosis. Semin Ophthalmol. 2013. doi:10.​1007/​s801090000086.PubMed
6.
go back to reference Boni C, Kordic H, Chaloupka K. Bisphosphonate-associated orbital inflammatory disease and uveitis anterior--a case report and review. Klin Monbl Augenheilkd. 2013;230(4):367–9.CrossRefPubMed Boni C, Kordic H, Chaloupka K. Bisphosphonate-associated orbital inflammatory disease and uveitis anterior--a case report and review. Klin Monbl Augenheilkd. 2013;230(4):367–9.CrossRefPubMed
7.
go back to reference Albani-Campanario M, Buendia-Diaz G, Flores-Islas Mde L, Maquita-Nakano C, Ochoa-Cervantes J. Zoledronic acid-based uveitis: a case report and a bibliography review. Ginecol Obstet Mex. 2012;80(5):355–9.PubMed Albani-Campanario M, Buendia-Diaz G, Flores-Islas Mde L, Maquita-Nakano C, Ochoa-Cervantes J. Zoledronic acid-based uveitis: a case report and a bibliography review. Ginecol Obstet Mex. 2012;80(5):355–9.PubMed
8.
go back to reference Peterson JD, Bedrossian Jr EH. Bisphosphonate-associated orbital inflammation--a case report and review. Orbit. 2012;31(2):119–23.CrossRefPubMed Peterson JD, Bedrossian Jr EH. Bisphosphonate-associated orbital inflammation--a case report and review. Orbit. 2012;31(2):119–23.CrossRefPubMed
9.
go back to reference Banal F, Briot K, Ayoub G, Dougados M, Roux C. Unilateral anterior uveitis complicating zoledronic acid therapy in prostate cancer. J Rheumatol. 2008;35(12):2458–9.CrossRefPubMed Banal F, Briot K, Ayoub G, Dougados M, Roux C. Unilateral anterior uveitis complicating zoledronic acid therapy in prostate cancer. J Rheumatol. 2008;35(12):2458–9.CrossRefPubMed
10.
go back to reference Kilickap S, Ozdamar Y, Altundag MK, Dizdar O. A case report: zoledronic acid-induced anterior uveitis. Med Oncol. 2008;25(2):238–40.CrossRefPubMed Kilickap S, Ozdamar Y, Altundag MK, Dizdar O. A case report: zoledronic acid-induced anterior uveitis. Med Oncol. 2008;25(2):238–40.CrossRefPubMed
11.
go back to reference Moore MM, Beith JM. Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer. Med J Aust. 2008;188(6):370–1.PubMed Moore MM, Beith JM. Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer. Med J Aust. 2008;188(6):370–1.PubMed
12.
go back to reference Woo TC, Joseph DJ, Wilkinson R. Serious ocular complications of zoledronate. Clin Oncol (R Coll Radiol). 2006;18(7):545–6.CrossRef Woo TC, Joseph DJ, Wilkinson R. Serious ocular complications of zoledronate. Clin Oncol (R Coll Radiol). 2006;18(7):545–6.CrossRef
13.
14.
go back to reference Durnian JM, Olujohungbe A, Kyle G. Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy. Eye (Lond). 2005;19(2):221–2.CrossRef Durnian JM, Olujohungbe A, Kyle G. Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy. Eye (Lond). 2005;19(2):221–2.CrossRef
15.
go back to reference Ryan PJ, Sampath R. Idiopathic orbital inflammation following intravenous pamidronate. Rheumatology (Oxford). 2001;40(8):956–7.CrossRef Ryan PJ, Sampath R. Idiopathic orbital inflammation following intravenous pamidronate. Rheumatology (Oxford). 2001;40(8):956–7.CrossRef
16.
go back to reference Subramanian PS, Kerrison JB, Calvert PC, Miller NR. Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer. Arch Ophthalmol. 2003;121(9):1335–6.CrossRefPubMed Subramanian PS, Kerrison JB, Calvert PC, Miller NR. Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer. Arch Ophthalmol. 2003;121(9):1335–6.CrossRefPubMed
17.
go back to reference Mbekeani JN, Slamovits TL, Schwartz BH, Sauer HL. Ocular inflammation associated with alendronate therapy. Arch Ophthalmol. 1999;117(6):837–8.PubMed Mbekeani JN, Slamovits TL, Schwartz BH, Sauer HL. Ocular inflammation associated with alendronate therapy. Arch Ophthalmol. 1999;117(6):837–8.PubMed
19.
go back to reference Dalle Carbonare L, Zanatta M, Gasparetto A, Valenti MT. Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf. 2010;2:121–37.CrossRefPubMedPubMedCentral Dalle Carbonare L, Zanatta M, Gasparetto A, Valenti MT. Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf. 2010;2:121–37.CrossRefPubMedPubMedCentral
20.
go back to reference Patel DV, Horne A, Mihov B, Stewart A, Reid IR, McGhee CN. The Effects of Re-challenge in Patients with a History of Acute Anterior Uveitis Following Intravenous Zoledronate. Calcif Tissue Int. 2015;97(1):58–61.CrossRefPubMed Patel DV, Horne A, Mihov B, Stewart A, Reid IR, McGhee CN. The Effects of Re-challenge in Patients with a History of Acute Anterior Uveitis Following Intravenous Zoledronate. Calcif Tissue Int. 2015;97(1):58–61.CrossRefPubMed
21.
go back to reference Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010;95(9):4380–7.CrossRefPubMed Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010;95(9):4380–7.CrossRefPubMed
22.
go back to reference Cavallasca JA, Reyt C. [Acute anterior uveitis associated with the use zoledronic acid]. Medicina (B Aires). 2014;74(5):428–9. Cavallasca JA, Reyt C. [Acute anterior uveitis associated with the use zoledronic acid]. Medicina (B Aires). 2014;74(5):428–9.
23.
go back to reference Belliveau MJ, Almeida DR, Urton TE. Acute anterior uveitis following zoledronic acid infusion for osteoporosis. Can J Ophthalmol. 2012;47(5):e22–3.CrossRefPubMed Belliveau MJ, Almeida DR, Urton TE. Acute anterior uveitis following zoledronic acid infusion for osteoporosis. Can J Ophthalmol. 2012;47(5):e22–3.CrossRefPubMed
25.
go back to reference Colucci A, Modorati G, Miserocchi E, Di Matteo F, Rama P. Anterior uveitis complicating zoledronic acid infusion. Ocul Immunol Inflamm. 2009;17(4):267–8.CrossRefPubMed Colucci A, Modorati G, Miserocchi E, Di Matteo F, Rama P. Anterior uveitis complicating zoledronic acid infusion. Ocul Immunol Inflamm. 2009;17(4):267–8.CrossRefPubMed
27.
go back to reference Yang EB, Birkholz ES, Lee AG. Another case of bisphosphonate-induced orbital inflammation. J Neuroophthalmol. 2010;30(1):94–5.CrossRefPubMed Yang EB, Birkholz ES, Lee AG. Another case of bisphosphonate-induced orbital inflammation. J Neuroophthalmol. 2010;30(1):94–5.CrossRefPubMed
28.
go back to reference Etminan M, Forooghian F, Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. CMAJ. 2012;184(8):E431–4.CrossRefPubMedPubMedCentral Etminan M, Forooghian F, Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. CMAJ. 2012;184(8):E431–4.CrossRefPubMedPubMedCentral
29.
go back to reference Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2005;139(1):101–11.CrossRefPubMedPubMedCentral Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2005;139(1):101–11.CrossRefPubMedPubMedCentral
Metadata
Title
Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report
Authors
Yiming Tian
Rui Wang
Lianyuan Liu
Chunming Ma
Qiang Lu
Fuzai Yin
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2016
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-016-0926-x

Other articles of this Issue 1/2016

BMC Musculoskeletal Disorders 1/2016 Go to the issue